
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences Inc. is demonstrating promising advancements in its clinical pipeline for treating Duchenne muscular dystrophy (DMD), highlighted by favorable reductions in clinical biomarkers of muscle damage, indicating improved muscle integrity in patients. Initial data from the INSPIRE DUCHENNE study reveals strong results in vector transduction and microdystrophin expression, alongside potential cardiac benefits, enhancing the company's therapeutic prospects. Furthermore, the SGT-003 treatment exhibits a favorable safety profile with minimal adverse events reported, reinforcing the company's capability to deliver effective and safe therapies for severe neuromuscular diseases.
Bears say
Solid Biosciences Inc. faces a negative outlook primarily due to the regulatory uncertainties surrounding its lead product, SGT-003, for the treatment of Duchenne muscular dystrophy (DMD); without regulatory approval, the company’s risk-adjusted financial projections could be significantly downgraded. Additionally, the company's potential sales of SGT-003 may be jeopardized if it fails to develop adequate manufacturing capacity, which could limit its ability to meet market demand. Overall, these factors create substantial risks that could hinder the company's growth and financial stability moving forward.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares